5 Key Takeaways

• 1

  The FDA issued draft guidance to streamline biosimilar drug development and reduce costs.

• 2

  The proposal aims to simplify biosimilarity assessments and minimize unnecessary clinical trials.

• 3

  Biosimilars currently hold less than 20% of the market despite their therapeutic equivalence to branded biologics.

• 4

  Since 2015, the FDA has authorized 76 biosimilars, a small fraction compared to over 30,000 approved generic drugs.

• 5

  The new guidance reflects the FDA's experience and indicates that comparative efficacy studies are often unnecessary.